Product Images Imatinib

Imatinib Mesylate Tablets are intended for institutional use only and come in a 100mg strength. The tablets are packaged in a bottle containing 30 tablets, which are further divided into three unit-dose packs of 10 tablets each. The manufacturer of these tablets is Dr. Reddys. The NDC code for these tablets is 43598-344-31.*

Imatinib Mesylate Tablets 400 mg is a prescription medicine packed in a unit-dose package of 30 tablets and is for institutional use only. The NDC number for the medicine is 43598-345-31, and the tablets are manufactured by Dr. Reddy's Laboratories Ltd. Each coated tablet contains Imatinib mesylate equivalent to Imatinib 400 mg. Additional information about the storage of the medicine is provided in the text.*

This is the description of a medicine called Imatinib Mesylate, which is dispensed in a container with 90 tablets of 100mg each. The recommended dosage can be found in the package insert. It is advised to store the medicine at room temperature, and out of reach of children. It is manufactured by Dr.Reddy and the address of the company is mentioned. The last few lines contain some unclear characters, and cannot be evaluated.*

The given text describes a medication named "Imatinib Mesylate Tablets" with a dosage of 400mg. The medication is coated with a film and comes in a tightly sealed container that protects it from moisture. The text includes the usual dosage instructions and also mentions the distributor, which is Dr. Reddy's Laboratories based in Princeton, NJ. The medication is made in India and the text also includes storage instructions and a warning to keep it out of children's reach. Overall, the text provides essential information about the medication for patients and healthcare providers.*

This appears to be a table or graph with statistics regarding number of patients and hazard ratio for two different treatment arms. The treatment arms are Imatinib Mesylate and IFl+Ara-C. The table also has information about patients who were censored at discontinuation and at the time of the last follow-up. The hazard ratio is given as 0.37-0.48 with a Log-rank Test P-value less than 0.0001. There is a reference to "Months Since Randomization". No other details or context are provided.*

This text seems to be a table showing the number of patients and results of a study comparing the efficacy of Imatinib Mesylate and IFNsAra-C for patients with AP (accelerated phase) or BG (blast crisis) evidenced by their disease's progression. The table shows how many patients were censored at discontinuation and last follow-up, and the results of the hazard ratio of the two arms (Imatinib Mesylate and IFNsAra-C). The Log-rank Test indicates that there is a significant statistical difference between the two arms. The last row mentions "Months Since Randomization," which could be the time the study was conducted.*